Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Qualigen Therapeutics has signed a contract with STA Pharmaceutical, a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials.
Lead Product(s): AS1411
Therapeutic Area: Infections and Infectious Diseases Product Name: AS1411
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Qualigen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 05, 2020